V.Rengasamy, - (1.) AN application for patent claiming Switzerland priority date of July 18, 1997 was filed by M/s. Novartis AG on July 17, 1998 for an invention titled "Crystal Modification of A.N.-Phenyl-2-Pyrimidineamine derivative, processes for its manufacture and its use" and the same was allotted the application No. 1602/MAS/1998.
(2.) A representation by way of opposition tinder Section 25(1) of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005 was filed by M/s. Hetero Drugs Ltd., India, on August 22, 2005 with a request for hearing under Rule 55 of the Patents Rules, 2003 as amended by Patents (Amendment) Rules, 2005. The Applicant through their agents M/s. Remfry & Sagar, New Delhi filed reply statement along with evidence by way of affidavit affirmed by Dr. Paul William Manley of Switzerland November 14, 2005. In their reply statement, the Applicant had requested for a hearing under Rule 55 of the Patents Rules, 2003. They filed another affidavit affirmed by Giorgio Pietro Massimini of Switzerland.
(3.) BEFORE discussing the grounds of opposition, it is pertinent to briefly mention here the background of the application. The present application claims -crystal form of methanesulphonic acid salt of 4-(4-methylpiperazin-1-ylemethyl)-N-[4-methyl-3-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide commercially called as imatinib mesylate. Invention of the base compound, 4-(4-methylpiperazin-1-vlmethyl)-N-[4-methyl-3-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide called as imatinib had already been disclosed in the European Patent publication No. EP-A-056409, published on October 6, 1993, and its equivalent US Patent No. 5521184, etc. Priority:;